$SPRCAug 5, 2026, 12:26 PMAI processed
SciSparc/NeuroThera launches Phase IIb SCI-110 Tourette trial site at Yale
AI Summary
SciSparc’s majority-owned NeuroThera has opened a Phase IIb site at the Yale Child Study Center to evaluate SCI-110, an oral cannabinoid formulation (dronabinol + palmitoylethanolamide) for adults with Tourette syndrome in a randomized, double-blind, placebo-controlled crossover trial measuring tic change by the Yale Global Tic Severity Scale at weeks 12 and 26. The study is part of a multicenter program (also in Germany and Israel) and builds on a Phase IIa that reported a 21% average tic reduction, so a positive Phase IIb could materially de-risk development—but efficacy to date is modest and the trial is ongoing.
Positives
- Phase IIb trial site initiated at Yale Child Study Center (adds a high-profile U.S. site)
- Trial is randomized, double-blind, placebo-controlled crossover (robust design)
- Phase IIa showed a 21% average tic reduction on the Yale Global Tic Severity Scale
Negatives
- Phase IIa effect size was modest (21% average tic reduction)
- Current Phase IIb is adult-only (ages 18–65), excluding pediatric TS population
- Efficacy and regulatory outcomes remain uncertain while the trial is ongoing